Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed) | RFA DK 19 505

Opportunity Information: Apply for RFA DK 19 505

This grant opportunity, RFA-DK-19-505, is a limited, one-time NIH Funding Opportunity Announcement designed specifically for the current awardee institution that already runs the Accelerating Medicines Partnership (AMP) Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D effort is a large public-private partnership involving NIH, pharmaceutical companies, and nonprofit organizations, built around a shared goal: speeding up the identification and validation of biological targets that could become biomarkers or lead to new drug discovery approaches for type 2 diabetes and related complications. Rather than funding a brand-new program, this FOA is essentially a continuation and expansion mechanism intended to keep the existing portal evolving and to position it as the central, "flagship" resource for understanding the biological heterogeneity seen across people with T2D.

The core purpose of the award is to support the next five-year phase of development for the web portal and its underlying curated knowledge base. The portal is expected to grow in both breadth and depth, meaning it should expand the range of datasets and traits it includes, bring in additional types of data beyond what is already hosted, and add more analytical and visualization capabilities that help users interpret complex diabetes-related biology. A major emphasis is improving usefulness for a broader and more diverse user community, which typically implies better usability, documentation, and tools that work for researchers with different levels of computational expertise, as well as content that reflects varied populations and disease presentations.

A key operational feature of the FOA is its cooperative agreement mechanism (UM1), which signals substantial NIH involvement during the project. In practice, this usually means the portal team is expected to coordinate closely with NIH program staff on priorities, milestones, and consortium-level decisions. Clinical trials are explicitly not allowed under this announcement, keeping the work focused on knowledge aggregation, curation, data integration, and tool development rather than interventional human studies.

The portal is also expected to play a coordinating role across a broader AMP T2D Consortium. Specifically, it will work closely with companion Functional Genomic Project awardees funded under a separate announcement (RFA-DK-19-012). The Knowledge Portal functions as a hub for the consortium by supporting collaboration, helping align datasets and standards, and enabling the broader community to access and analyze outputs. In addition, the award includes an "opportunity pool" of funds that the portal leadership will oversee to solicit and support collaborative projects that advance consortium objectives. That pool is essentially a flexible funding mechanism to catalyze targeted collaborations, fill gaps, or accelerate high-value integrations and tool-building efforts that emerge during the project period.

Eligibility is deliberately narrow. The FOA is limited competition, inviting an application from the current awardee institution of the AMP T2D Knowledge Portal. The eligible applicant category listed is public and state-controlled institutions of higher education, consistent with the current awardee profile. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply; however, foreign components as defined by the NIH Grants Policy Statement are allowed, meaning certain types of international collaboration may be permissible when structured as an allowable foreign component rather than as a foreign applicant or non-domestic organizational component.

From an administrative and funding standpoint, the opportunity is categorized as discretionary and uses the cooperative agreement funding instrument. It sits within NIH’s health-related mission space (CFDA 93.847). The original closing date for applications was December 3, 2019, and the FOA was created on September 27, 2019. The listed award ceiling is $3,000,000, and the announcement indicates expected awards without specifying a number in the provided excerpt, which aligns with the limited-competition, single-awardee continuation nature of the program.

Overall, this FOA is aimed at sustaining and scaling a major national data and analytics resource for type 2 diabetes by expanding the portal’s content, improving analytic and visualization tooling, coordinating consortium-wide activities with functional genomics partners, and strategically funding collaborative projects that help the consortium deliver on its translational goal of clarifying disease biology and accelerating target discovery.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2019-09-27.
• Applicants must submit their applications by 2019-12-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $3,000,000.00 in funding.
• Eligible applicants include: Public and State controlled institutions of higher education.

Apply for RFA DK 19 505

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: